Table 3. Area under the receiver-operator characteristic curve for 10 years regarding overall survival and disease-free survival for Adjuvant! Online and Nottingham Prognostic Index by age group and tumour subtype.
|
Overall survival |
Disease-free survival |
|||
|---|---|---|---|---|
| AUC for time-point 10 years (95% CI) | P-value AOL vs NPI | AUC for time-point 10 years (95% CI) | P-value AOL vs NPI | |
|
Young cohort | ||||
| All (n=376) | ||||
| AOL | 73.1 (66.1–80.2) | 0.45 | 66.0 (59.6–72.4) | 0.51 |
| 6-class NPI | 71.9 (65.0–78.7) | 64.6 (58.2–71.1) | ||
| ER+/HER2−(n=181) | ||||
| AOL | 67.2 (56.2–78.2) | 0.44 | 64.2 (54.9–73.5) | 0.45 |
| 6-class NPI | 69.0 (58.6–79.4) | 66.5 (57.5–75.5) | ||
| ER−/HER2−(n=86) | ||||
| AOL | 76.4 (63.9–88.8) | 0.91 | 60.9 (46.9–74.9) | 0.90 |
| 6-class NPI | 76.7 (63.8–89.6) | 60.4 (46.1–74.7) | ||
| HER2+(n=74) | ||||
| AOL | 75.4 (60.7–90.1) | 0.06 | 73.8 (60.5–87.1) | 0.03 |
| 6-class NPI | 68.2 (51.1–85.2) | 62.9 (48.0–77.8) | ||
|
Older cohort | ||||
| All (n=907) | ||||
| AOL | 74.0 (69.0–79.1) | 0.94 | 63.5 (58.8–68.2) | 0.35 |
| 6-class NPI | 74.1 (69.1–79.1) | 64.9 (60.3–69.5) | ||
| ER+/HER2−(n=591) | ||||
| AOL | 71.9 (64.9–78.9) | 0.80 | 63.7 (57.5–69.8) | 0.59 |
| 6-class NPI | 72.2 (65.3–79.1) | 64.8 (58.8–70.8) | ||
| ER−/HER2−(n=76) | ||||
| AOL | 61.5 (45.8–77.3) | 0.98 | 59.8 (44.1–75.5) | 0.31 |
| 6-class NPI | 61.6 (45.6–77.6) | 63.6 (48.2–79.0) | ||
| HER2+(n=102) | ||||
| AOL | 76.2 (62.8–89.5) | 0.24 | 63.0 (49.7–76.2) | 0.22 |
| 6-class NPI | 80.2 (68.9–91.4) | 68.4 (56.0–80.9) | ||
Abbreviations: AOL=Adjuvant! Online; AUC=area under the receiver-operator characteristic curve; CI=confidence interval; ER=oestrogen receptor; HER2=human epidermal growth factor receptor 2; NPI=Nottingham Prognostic Index.